Avadel Pharmaceuticals PLC
AVDL
查看详细走势图
21.690USD
+0.090+0.42%
收盘 02/06, 16:00（美东）报价延迟15分钟
2.11B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.42%
5天
+0.65%
1月
+0.88%
6月
+95.41%
今年开始到现在
+0.65%
1年
+171.13%
查看详细走势图
TradingKey Avadel Pharmaceuticals PLC股票评分
单位: USD 更新时间: 2026-02-06操作建议
Avadel Pharmaceuticals PLC当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名53/159位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价21.06。中期看，股价处于上升通道。近一个月，市场表现一般，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Avadel Pharmaceuticals PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
极度看空
Avadel Pharmaceuticals PLC亮点
亮点风险
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
估值低估
公司最新PE估值-12465.52，处于3年历史低位
机构加仓
最新机构持股92.83M股，环比增加3.78%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值843.00
分析师目标
根据
10
位分析师
持有
评级
21.056
目标均价
-2.52%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Avadel Pharmaceuticals PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Avadel Pharmaceuticals PLC简介
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
公司代码AVDL
公司Avadel Pharmaceuticals PLC
CEODivis (Gregory J)
网址https://www.avadel.com/
相关品种
